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Background: In renal cell carcinoma (RCC), the prediction of metastasis via tumor prognostic markers remains a major problem. The
objective of our study was to evaluate the efﬁcacy of cyclin-dependent kinase (CDK)1 and CDK2 activity as a prognostic marker in
human RCC.
Methods: Surgical specimens were obtained from 125 patients with RCC without metastasis. Protein expression and kinase activity of
CDKs were analyzed using a newly developed assay system named C2P (Sysmex, Kobe, Japan). We then examined the speciﬁc activities
(SAs) of CDK1 and CDK2 and calculated CDK2SA-CDK1SA ratio in RCC. Also, risk score (RS) was examined.
Results: A total of 125 cases were tested, though 34 cases were excluded because of low sample quality (25 cases) and assay failure
(9 cases). In total, 91 cases were analyzed. They included 68 male and 23 female patients, ranging in age from 19 to 83 years. At a median
follow-up of 36 months (1–109M), tumor with low CDK2SA-CDK1SA ratio showed signiﬁcantly better 5-year recurrence-free survival than
those with high CDK2SA-CDK1SA ratio (88.7% vs. 54.7%, P ¼ 0.00141). Also, RS enabled the classiﬁcation of RCCs into high-risk and
low-risk groups, and patients with tumors classiﬁed as low RS showed better recurrence-free survival than patients with tumors with high RS
(88.7% vs. 54.7%, P ¼ 0.0141).
Conclusion: CDK1SA of tumors and the CDK2SA are both associated with recurrence and prognosis.
Impact: CDK-based risk demonstrated is strongly associated with clinical outcome. CDK-based risk should be an accurate system for
predicting recurrence and survival for planning follow-up. r 2014 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Renal cell carcinoma (RCC) accounts for approximately
3% of adult malignancies and 90% of neoplasm arising
from the kidney. Approximately 40% of human RCCs are
currently diagnosed incidentally. It is estimated that there.urolonc.2014.05.006
uthors. Published by Elsevier Inc. This is an open acc
rg/licenses/by-nc-nd/3.0/).
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@koto.kpu-m.ac.jp (F. Hongo).were 36,000 new cases of RCC in the United States in 2006
with almost 13,000 deaths [1]. Of patients after radical
nephrectomy for localized RCC, 30% experience local or
distant tumor recurrence [2].
Clinical and pathological staging according to the TNM
system has served as a standard for predicting prognosis,
but predicting value is not accurate enough for localized
cancer [3,4]. Some nomograms based on clinical and
pathological parameters have been discussed for predictingess article under the CC BY-NC-ND license
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molecular markers that reﬂect the individual tumor behavior
should improve patient management after surgery.
Recently, molecules involved in cell cycle regulation,
such as cyclins, cyclin-dependent kinases (CDKs), and
CDK inhibitors, have been attracting considerable attention
as potential prognostic indicators [7–9].
We have been focusing on CDKs (CDK1 and CDK2)
and investigating their prognostic signiﬁcance in breast
cancers because CDKs play a pivotal role in cell cycle
regulation [10,11]. The CDK expression levels are almost
constant but their activities change markedly according to
the cell cycle phase. Thus, it is necessary to measure CDK
activities themselves to accurately evaluate the role of
CDKs in cell proliferation. Recently, we succeeded in
developing a system that can assay the speciﬁc activity
(SA) of CDKs using small tissue samples [12]. The
clinical utility of the technology was ﬁrst evaluated in
breast cancer, and combination analysis of CDK1 and
CDK2 activity was shown to be a signiﬁcant prognostic
indicator for relapse [13,14]. The objective of this study
was to clarify the prognostic implications of CDKSA
in RCCs.2. Material and methods
2.1. Patients
For this study, 158 patients who had undergone radical
nephrectomy between September 1999 and August 2009
were recruited. These patients were selected randomly for
this study. The following data were available: age at
diagnosis, histological type, TNM stage, local and system-
atic therapy, recurrence, and overall survival. No tyrosine
kinase inhibitor (TKI), mammalian target of rapamycin
inhibitor, or immunotherapy (interferon alfa alone or with
IL-2) was administrated before recurrence.
2.2. Assay for CDKSA
Tumor tissue was dissected from the surgical resection
and stored at 801C in the Department of Urology, Kyoto
Prefectural University of Medicine. The system to measure
the CDKSA is called “C2P” (for “Cell Cycle Proﬁling”;
Sysmex, Kobe, Japan). In brief, lysates of frozen material
were applied to a well of 96-well polyvinylidene ﬂuoride
ﬁlter plate (Millipore, MA). Expression of CDKs was
detected quantitatively by sequential reactions with primary
anti-CDK antibodies, biotinylated antirabbit antibodies, and
ﬂuorescein-labeled streptavidin. To measure the kinase
activity, CDK molecules were immunoprecipitated from
the tissue lysate using protein beads, as reported in detail
earlier [1,2]. The thiophosphate of adenosine 50-[γ-thio]
triphosphate was transferred to the protein substrate during
the on-bead kinases reaction. The introduced thiophosphatewas labeled further with 5-iodoacetamidoﬂuorescein and
blotted onto a well of the ﬁlter plate. The kinase activity
was determined by measuring the ﬂuorescence intensity
of the well. CDKSA was calculated as CDK activity units
(aU/ml lysate) divided by its corresponding CDK expression
units (eU/ml lysate). Both aU (CDK activity unit) and eU
(CDK expression unit) were deﬁned as the expression and
activity equivalent to 1 ng of recombinant active CDK1 and
CDK2, respectively.
The blood contamination is visually determined by using
a color bar of redness. The ranges from dark to faint and is
graded 1 to 10. Only qualiﬁed technicians who passed the
technical examination conduct the C2P assay with patient's
samples.
Affection of the blood contamination was examined with
lysates of human cell line spiked with various amount of
human blood. In results, blood contamination of score 4 and
more of redness showed signiﬁcant error (410%) in
expression assays of both CDK1 and CDK2. By contrast,
the activity assay was quite robust against the blood
contamination, as a step of bound/free separation is in the
activity assay, but not in the expression assay.
According to the aforementioned results, the samples
with blood contamination of score 4 and more of redness
were excluded from the C2P analysis.
2.3. Statistical methods
Association between clinicopathological characteristics
and the C2P parameters were examined in the chi-square
test. Recurrence-free survival (RFS) according to C2P
parameters was analyzed with the Kaplan-Meier plot, and
the differences of RFS in each category were assessed with
the log-rank test. The Cox proportional hazards model was
used for both univariate and multivariate analyses. Test
results were considered signiﬁcant at Po 0.05.3. Results
3.1. Patients
Of 158 patients, 25 were excluded because of poor
sample quality with severe blood contamination. In total, 11
patients were excluded from our study because of clinical
exclusion (benign: 1, nonrenal cancer: 2, metastatic tissue:
2, and treatment with TKIs: 5). Of the cases, 9 were non-
informative cases of the assay. A total of 26 patients
developed recurrence (the lung, liver, bone, etc.). Of these
113 patients, 22 patients with metastases were excluded for
analysis of RFS and overall survival. Of the 91 cases,
the median follow-up period was 37 months (1–121M), and
the RFS rate at 5 years was 84.6 % (77/91). They included
68 male and 23 female patients, ranging in age from 19 to




Parameters Category n %
Age, y 460 67 59.3
r60 46 40.7
Sex Male 84 74.3
Female 29 25.7







N N0 98 86.7
N1 12 10.6
N2 3 2.7




Grade 1 7 6.2
2 67 59.3
3 39 34.5
T size, cm o4 33 29.2
4–7 39 34.5
47 41 36.3
Histology Belini 1 0.9
Chromophobe 3 2.7
Clear cell 91 80.5
Oncocytoma 2 1.8
Papillary 10 8.8
Papillary þ sarcomatoid 1 0.9
Sarcomatoid 4 3.5
Unclassiﬁed 1 0.9
Event Recurrence 26 23.0
Dead 11 9.7
Median RFS, mo 20
Median OS, mo 29
Surgical specimens were obtained from 147 patients with renal cell
carcinoma. These patients were selected randomly for this study. The
median patient age was 64 years (range: 19–85). Overall, 72.5% had stage
I or II disease and 61.5% were diagnosed as clear cell carcinoma. The
median follow-up period was 37 months (range: 1–121M), and the
recurrence-free survival (RFS) rate in all patients tested at 5 years after
surgery was 84.6% (77/91). Metastatic cases were excluded from our
analysis (22 cases). OS ¼ overall survival.
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The cases were then categorized into 2 groups by the
optimal cutoff point determined in receiver operating
characteristic (ROC) analysis of respective parameter:
CDK1SA, CDK2SA, CDK2SA-CDK1SA ratio, or C2P
risk score (C2P-RS). The cutoff values for CDK1SA,
CDK2SA, and CDK2SA-CDK1SA ratio were deﬁned asthe points that gave the best discrimination in RFS by
receiver operating characteristic curve (Fig. 1). The optimal
cutoff values of CDK1SA and of CDK2SA for recurrence
prediction are 4.8 and 7.2, respectively. The cutoff value
CDK2SA-CDK1SA ratio is 1.3. C2P-RS was given by the
following equations:
C2P-RS ¼ Equation 1  Equation 2  3; 000
Equation 1 ¼ 0:25= 1 þ Exp – x – 1:0ð Þ  6ð Þð Þ;
x ¼ log CDK2SA=CDK1SA 
Equation 2 ¼ 0:15= 1þExp – y – 1:6ð Þ  7ð Þð Þ;
y ¼ log CDK1SAð Þ
3.3. Correlation analysis of C2P parameters with
clinicopathological characteristics
The correlation of various clinicopathological parameters
and C2P parameters is shown in Table 2. High stage and
high grade showed signiﬁcantly poor prognosis but tumor
size showed no correlation with 5-year RFS in this study.
The C2P parameters did not show any statistically signiﬁ-
cant correlations with tumor size. By contrast, the categories
showed signiﬁcant correlations with clinical stage and
tumor grade (Tables 3).3.4. Signiﬁcance of each C2P parameters for recurrence
prediction
Next, we studied the relationship of the combination of
CDK1SA and CDK2SA with prognosis. Patients with high
CDK1 or high CDK2SA tumors or both showed poor
prognosis (5-y RFS rate was 84.6% [77/91]), whereas
patients with tumors in which both CDK1SA and CDK2SA
were less than lower measurement limits showed good
prognosis.
Tumors with low CDK2SA-CDK1SA ratio showed
signiﬁcantly better 5-year RFS than those with high
CDK2-CDK1 ratio (88.7% vs. 54.7%, P ¼ 0.00141).
Also, RS enabled the classiﬁcation of RCCs into high-risk
and low-risk groups, and patients with tumors classiﬁed as
low RS showed better RFS than patients with tumors with
high RS (88.7% vs. 54.7%, P ¼ 0.0141) (Fig. 2).
The Cox proportional hazards model revealed that
clinical staging and tumor grade were signiﬁcant prognostic
factors for RFS in all patients tested (stage: P ¼ 0.041,
hazard ratio [HR] ¼ 3.025; grade: P ¼ 0.009, HR ¼
4.06). Among the C2P parameters, CDK2SA, CDK2SA-
CDK1SA ratio, and C2P-RS showed signiﬁcance in the
analysis, but CDK1SA did not (CDK1SA: P ¼ 0.051,
HR ¼ 2.98; CDK2SA: P ¼ 0.044, HR ¼ 2.98; CDK
2SA-CDK1SA ratio: P ¼ 0.021, HR ¼ 3.47; CDK-RS:
P ¼ 0.041, HR ¼ 3.12, respectively) (Fig. 3).
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Sensitivity : 57.1 %





Sensitivity : 57.1 %





Sensitivity : 57.1 %
Specificity : 71.4 % 
A)  CDK1SA
C)  CDK2SA/CDK1SA ratio
B)  CDK2SA
D)  C2P-RS
Fig. 1. Setting of an optimal cutoff value for recurrence prediction in renal cancer by the ROC analysis: (A) CDK1-speciﬁc activity, (B) CDK2-speciﬁc
activity, (C) CDK2SA-CDK1SA ratio, and (D) C2P-RS. ROC ¼ receiver operating characteristic.
Table 2
Correlation analysis of C2P parameters with clinicopathological characteristics
Parameters Category C2P-RS CDK2SA-CDK1SA ratio
Low High Signiﬁcancea (P value) Low High Signiﬁcancea (P value)
Stage 1 32 20 52 (57.1%) 40 12 52 (57.1%)
2 11 2 13 (14.3%) 8 5 13 (14.3%)
3 12 8 20 (22.0%) 13 7 20 (22.0%)
4 1 5 6 (6.6%) 0.0450 2 4 6 (6.6%) 0.1326
Grade 1 6 1 7 (7.7%) 7 0 7 (7.7%)
2 39 24 63 (69.2%) 45 18 63 (69.2%)
3 11 10 21 (23.1%) 0.2899 11 10 21 (23.1%) 0.0485
Size o4 19 10 29 (32.2%) 24 5 29 (32.2%)
4–7 19 12 31 (34.4%) 20 11 31 (34.4%)
47 18 12 30 (33.3%) 0.9010 18 12 30 (33.3%) 0.1363
The C2P parameters did not show any statistically signiﬁcant correlations with tumor size. By contrast, the categories showed signiﬁcant correlations with
clinical stage and tumor grade.
aChi-square test.
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Table 3
Cox regression hazards model analysis
Parameters Criteria Hazard ratio 95% CI of HR Signiﬁcance
Univariate
Age, y 460 vs.r60 0.7433 0.2560–2.1584 0.5874
Stage 1 vs. 2, 3, 4 1.6665 0.5870–4.7315 0.3399
1, 2 vs. 3, 4 3.0254 1.0516–8.7041 0.04107
Grade 1 vs. 2, 3 10.8898 0.000–2.38E þ 180 0.9553
1, 2 vs. 3 4.0609 1.4294–11.5368 0.008866
T size o4 vs.Z4 cm 3.1899 0.7191–14.1508 0.1289
r7 vs.47 cm 1.214 0.4088–3.6052 0.7283
o4 vs. 4–7 vs.47 cm 1.4629 0.7570–2.8271 0.2601
C2P-RS L vs. H 3.1193 1.0507–9.2606 0.04149
CDK2-CDK1 ratio L vs. H 3.4733 1.2102–9.9680 0.02128
Multivariate
Stage 1, 2 vs. 3, 4 1.218 0.3280–4.5234 0.7694
Grade 1, 2 vs. 3 3.8954 1.0747–14.119 0.03948
C2P-RS L vs. H 3.2519 1.0692–9.8901 0.0387
Stage 1, 2 vs. 3, 4 1.4803 0.4437–4.9386 0.5255
Grade 1, 2 vs. 3 2.7201 0.8204–9.0187 0.1035
CDK2-CDK1 ratio L vs. H 2.6623 0.9039–7.8417 0.07714
Univariate and multivariate analyses were performed against clinical staging, tumor grade, and C2P-RS. C2P-RS was shown to be an independent and
signiﬁcant predictor against clinical staging and tumor grade (hazard ratio ¼ 3.25, P¼ 0.0387).
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In this study, we applied an original method enabling
simultaneous analysis of protein expressions and kinase
activities of the CDK molecules (C2P) to predict outcomes
in the patients with RCC. CDK1- and CDK2-SAs of tumors
are both associated with recurrence and prognosis. Multi-
variate analysis demonstrated that CDK-based risk was a
signiﬁcant prognostic indicator. More importantly, CDK-
based risk was a highly signiﬁcant and independent
prognostic indicator for nonmetastatic RCCs.
Both CDK1 and CDK2 are considered to play an
important role in cell proliferation and are expected to be
associated with tumor aggressiveness and a poor prog-
nosis [2,13,15,16]. Some studies have shown that CDK1
may be required for apoptosis that is independent of the
regulation of the cell cycle [17,18]. However, the prog-
nostic effect of activity of CDK1 or CDK2 has not been
investigated.
In RCC, the prediction of metastasis via tumor prog-
nostic markers remains a major problem. Various conven-
tional parameters, such as a tumor size, stages, and grades,
have been studied to identify subsets of patients with a
prognosis. Several molecular markers have been appearedto reﬁne the prognosis and prediction of RCC. Carbonic
anhydrase IX is one of studied markers in RCC. High
carbonic anhydrase IX expression in metastatic cases was
associated with better disease-speciﬁc survival [19], but not
in nonmetastatic cases.
The mammalian cell cycle is driven by a variety of
molecules regulating activities of CDKs [20]. Von Hippel
Lindau (VHL) is also supposed to be a key molecule of
RCC, because mutations of the VHL gene are a critical
event leading to development of RCC in both sporadic and
hereditary forms. This lack of VHL function leads to the
stabilization of both HIF1a and HIF2a proteins as well as an
increase in DNA damage. Furthermore, cyclin D1 is over-
expressed and remains inappropriately high during contact
inhibition in pVHL-deﬁcient RCC cell lines [21]. Contra-
rily, in a study in a mouse RCC cell line Renca, the over
expression of one of CDK inhibitors p21WAF1/CIP1 is a more
potent growth suppressor than p53 [22], though there are no
clinical studies of the signiﬁcance of p21 in RCC.
Other cell cycle–based markers were reported in RCC.
Ki-67 has been suggested as a tissue-based marker for
tumor aggressiveness in a lymph node–negative RCC, and
Ki-67 labeling index is predictive when used with other
factors [23]. Furthermore, p53 is an independent predictor























































































CDK1SA rec. case (%) all case (%) 
Low (< 4.8) 5 (9) 56 (62) 
High ( 4.8) 9 (26) 35 (38) 
Logrank test    p= 0.0396 
CDK2SA rec. case (%) all case (%) 
Low (< 7.2) 6 (10) 61 (67) 
High ( 7.2) 8 (27) 30 (33) 
Logrank test    p= 0.0341 
CDK2SA/CDK1SA ratio rec. case (%) all case (%) 
Low (< 1.3) 6 (10) 63 (69) 
High ( 1.3) 8 (29) 28 (31) 
Logrank test    p= 0.0141 
C2P-RS rec. case (%) all case (%) 
Low (< 0.0015) 5 (9) 56 (62) 
High ( 0.0015) 9 (26) 35 (38) 
Logrank test    p= 0.0314 
Fig. 2. Signiﬁcance of each C2P parameters for recurrence prediction. Progression-free survival (RFS) rates according to C2P parameters in renal cell
carcinoma (n ¼ 91) tested in this study: A strong prognostic signiﬁcance was observed in all C2P parameters using log-rank test. (A) CDK1-speciﬁc activity,
(B) CDK2-speciﬁc activity, (C) CDK2SA-CDK1SA ratio, and (D) C2P-RS.
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patients with localized RCC [24]. However, further studies
are required in this regard.
On the one hand, molecular targeting therapies, such as
TKIs and mammalian target of rapamycin inhibitors, have
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Fig. 3. Forest-plot of each parameter for recurrence prediction. The Cox
proportional hazards model revealed that clinical staging and tumor grade
were signiﬁcant prognostic factors for RFS in all patients tested (stage:
P ¼ 0.041, hazard ratio [HR] ¼ 3.025; grade: P ¼ 0.009, HR ¼ 4.06).
Among the C2P parameters, CDK2SA, CDK2SA-CDK1SA ratio, and
C2P-RS showed signiﬁcance in the analysis, but CDK1SA did not
(CDK1SA: P ¼ 0.051, HR ¼ 2.98; CDK2SA: P ¼ 0.044, HR ¼
2.98; CDK2-CDK1 ratio: P ¼ 0.021, HR ¼ 3.47; CDK-RS: P ¼ 0.041,
HR ¼ 3.12). (Color version of ﬁgure is available online.)limited and the biomarkers have been investigated to
improve the effectiveness. On the other hand, CDK
inhibitors have been developed intensively, and some are
undergoing clinical trials [25].5. Conclusion
We have shown that CDK-based risk demonstrated by
evaluating CDK1SA and CDK2SA is strongly associated
with clinical outcome especially for patients with non-
metastatic RCC. We consider that the CDK-based risk
should be a new prognostic factor and a routine laboratory
test. An accurate system for predicting recurrence and
survival is useful for planning follow-up. However, our
results need to be validated in a multicenter study with a
larger number of patients.6. Conﬂict of interest
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